Retatrutide: the triple agonist behind 28.7 percent weight loss in TRIUMPH-4

Key takeaways

• Retatrutide is a once-weekly subcutaneous synthetic peptide that activates the GIP, GLP-1, and glucagon receptors. Semaglutide activates one of those three (GLP-1) and tirzepatide activates two (GIP and GLP-1) .
• The Phase 2 trial (Jastreboff 2023 NEJM, n=338, 48 weeks) reported mean weight reductions of 8.7, 17.1, 22.8, and 24.2 percent at the 1, 4, 8, and 12 mg doses respectively versus 2.1 percent on placebo .
• The first Phase 3 readout (TRIUMPH-4, sponsor topline December 2025) randomized 445 adults with obesity or overweight and knee osteoarthritis (without diabetes) for 68 weeks; the 12 mg dose produced a 28.7 percent mean body weight reduction on the efficacy estimand, with corresponding WOMAC knee pain reductions .
• Secondary cardiometabolic findings at the top dose included a 14.0 mm Hg systolic blood pressure reduction plus reductions in non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein .
• Retatrutide is investigational. It has no FDA-approved label, no FDA-approved dose, and is not on the FDA bulk substances list for compounding. Six additional TRIUMPH Phase 3 readouts (obesity, type 2 diabetes, established cardiovascular disease, OSA, and a dedicated cardiovascular/kidney outcomes trial) are still pending .

What 'triple agonist' actually means

A receptor agonist is a molecule that binds a receptor and turns it on. Most modern obesity drugs are agonists at the glucagon-like peptide 1 (GLP-1) receptor: semaglutide (Wegovy, Ozempic), liraglutide, dulaglutide, and the oral small molecule orforglipron all sit in this single-receptor class. Activating the GLP-1 receptor slows gastric emptying, raises insulin secretion in a glucose-dependent way, and quiets central appetite circuits.

Tirzepatide (Mounjaro, Zepbound) added a second receptor: glucose-dependent insulinotropic polypeptide (GIP). GIP is a separate incretin hormone with effects on insulin release, adipose tissue, and (in the brain) appetite that overlap and extend the GLP-1 effect.

Retatrutide adds a third: the glucagon receptor. Glucagon is best known as the hormone that raises blood sugar in low-glucose states, but at the receptor level it also drives energy expenditure, hepatic fat oxidation, and lipolysis. The clinical bet behind retatrutide is that adding controlled glucagon agonism to the dual GIP and GLP-1 effect will push weight reduction further, primarily by raising the rate of fat burned rather than only suppressing intake .

How retatrutide differs from earlier GLP-1 therapies

The comparison most readers want is to semaglutide and tirzepatide, since those are the two FDA-approved drugs people already know. The honest answer is that direct trial comparisons do not exist yet: there is no published head-to-head trial of retatrutide against either drug. What does exist is side-by-side trial data at maximum studied doses.

• Semaglutide 2.4 mg in STEP-1 (Wilding 2021 NEJM, n=1,961, 68 weeks): about 14.9 percent mean body weight reduction in adults with overweight or obesity and no diabetes .
• Tirzepatide 15 mg in SURMOUNT-1 (Jastreboff 2022 NEJM, n=2,539, 72 weeks): about 20.9 percent mean body weight reduction in adults with obesity and no diabetes .
• Retatrutide 12 mg in Phase 2 (Jastreboff 2023 NEJM, n=338, 48 weeks): about 24.2 percent mean body weight reduction in adults with overweight or obesity .
• Retatrutide 12 mg in TRIUMPH-4 Phase 3 (sponsor topline December 2025, n=445, 68 weeks): about 28.7 percent mean body weight reduction on the efficacy estimand in adults with obesity plus knee osteoarthritis .

The Phase 2 result that put retatrutide on the map

The retatrutide Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine 2023) randomized 338 adults with a body mass index of 30 or higher, or 27 or higher with a weight-related comorbidity, to weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, for 48 weeks. The primary outcome was percent change in body weight at 24 weeks; the trial also followed weight to 48 weeks .

At 48 weeks, mean body weight had fallen by 8.7 percent at 1 mg, 17.1 percent at 4 mg, 22.8 percent at 8 mg, and 24.2 percent at 12 mg versus 2.1 percent on placebo. The weight curves had not yet plateaued at 48 weeks at the top doses, which left open the question of how much further the effect would go on a longer trial. That open question is part of what TRIUMPH was designed to answer .

Adverse events were dose-dependent and predominantly gastrointestinal: nausea, diarrhea, vomiting, and constipation, mostly mild to moderate. Treatment discontinuation due to adverse events ranged from about 6 to 16 percent across doses. Dose-related increases in heart rate were reported, consistent with the glucagon-receptor activity. No new safety signal outside the incretin-class profile was reported in Phase 2 .

TRIUMPH-4: the first Phase 3 readout

TRIUMPH-4 (ClinicalTrials.gov NCT05931367) is a Phase 3, randomized, double-blind, placebo-controlled trial in adults with obesity or overweight and symptomatic knee osteoarthritis, without type 2 diabetes. It randomized 445 participants 1:1:1 to weekly subcutaneous retatrutide 9 mg, retatrutide 12 mg, or placebo, with a treatment period of 68 weeks. Co-primary endpoints were percent change in body weight and change in the WOMAC pain subscale .

Topline results were announced by the trial sponsor on December 11, 2025 (the detailed peer-reviewed publication has not appeared at the time of writing). On the efficacy estimand (effect if treatment is taken as randomized), mean body weight reduction was 26.4 percent at 9 mg and 28.7 percent at 12 mg, versus 2.1 percent on placebo. On the more conservative treatment-policy estimand (effect including participants who discontinue), the reductions were smaller (about 20 percent at 9 mg and 24 percent at 12 mg) but still notably larger than placebo .

Pain and cardiometabolic effects beyond weight

TRIUMPH-4 was designed to capture knee osteoarthritis pain in parallel with weight, on the hypothesis that mechanical load and inflammation both fall when weight falls. The reported WOMAC pain subscale reductions at the active doses were about 4.0 to 4.5 points (from a baseline near 6), versus about 2.1 points on placebo. Roughly 12 to 14 percent of participants in the active arms reached complete pain freedom on post-hoc analysis, compared with about 4 percent on placebo .

Several cardiometabolic markers also moved. Systolic blood pressure fell by about 14.0 mm Hg at the 12 mg dose. Non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein all dropped at the active doses. These are secondary endpoints in TRIUMPH-4 and therefore informative but not confirmatory: hard cardiovascular outcomes (heart attack, stroke, cardiovascular death) require a dedicated outcomes trial, which is what TRIUMPH-Outcomes is designed to provide .

Why these markers matter for the broader read of the drug: obesity drives blood pressure, atherogenic lipid panels, and chronic low-grade inflammation. A drug that moves all three in the right direction at the same time as it produces large weight loss has a plausible mechanism to reduce downstream cardiovascular events. Plausible is not proven; only a hard-endpoint outcomes trial settles that question.

Adverse events and a new safety signal

Gastrointestinal adverse events in TRIUMPH-4 looked broadly class-typical for the incretin family: nausea, diarrhea, constipation, vomiting, and decreased appetite, more frequent in the active arms than placebo, mostly mild to moderate, and concentrated during dose escalation. Treatment discontinuations attributable to adverse events were uncommon. Class-typical warnings around pancreatitis, gallbladder disease, gastroparesis, and acute kidney injury secondary to severe dehydration apply to any drug acting on this axis .

A new signal that did not appear in Phase 2 was dysesthesia, an altered sense of touch in which normal sensations feel unusual or painful. Reported rates were about 8.8 percent at 9 mg and 20.9 percent at 12 mg versus 0.7 percent on placebo. Discontinuations attributable to dysesthesia were uncommon, and the sponsor has indicated it will be tracked across the remaining TRIUMPH readouts. Whether this is a triple-agonist-specific finding or an emergent dose-related signal of any incretin-class drug at sustained high exposure is not yet resolved .

What additional TRIUMPH studies might reveal

TRIUMPH is a four-trial registrational program enrolling more than 5,800 participants across nested basket designs, plus a dedicated outcomes trial. TRIUMPH-1 (NCT05929066) studies retatrutide in obesity without diabetes over 80 weeks, with subsets nested for knee osteoarthritis and obstructive sleep apnea. TRIUMPH-2 studies the same in adults with type 2 diabetes. TRIUMPH-3 studies retatrutide in Class II or III obesity with established cardiovascular disease. TRIUMPH-4 is the standalone knee-osteoarthritis trial whose results have already been announced .

The questions these trials are designed to answer go beyond a single weight-loss number. TRIUMPH-1 will quantify how much further weight loss runs in a longer (80-week) trial in a broader obesity population, and whether the curve actually flattens or keeps falling. TRIUMPH-2 will test whether the magnitude transfers to type 2 diabetes (where weight loss has historically been smaller in this drug class). TRIUMPH-3 will test whether a higher-risk, higher-BMI cardiovascular-disease population gains a similar effect. The companion TRIUMPH-Outcomes trial (NCT06383390) is the dedicated cardiovascular and kidney outcomes trial; its readout will determine whether the cardiometabolic marker shifts translate into reductions in major adverse events .

Regulatory status and compounding posture

Retatrutide is investigational. It has no FDA-approved label, no approved indication, and no approved dose. It is not on the FDA bulk substances list eligible for traditional compounding under section 503A. The drug is not legally available outside the trial program in the United States as of this writing.

Pharmacies and online vendors that sell substances labeled 'retatrutide' are not selling the FDA-investigated drug under any approved framework. The identity, purity, and dosing accuracy of those preparations cannot be assumed from the trial data. The TRIUMPH data discussed above were generated with sponsor-manufactured drug at trial-defined doses, with full pharmacovigilance, and they do not transfer to gray-market preparations. The FDA has separately flagged dosing-error and identity issues in the broader compounded GLP-1 space .

For research and educational purposes only. Not medical advice. Decisions about any GLP-1-class therapy should involve a qualified clinician who can review individual medical history, comorbidities, and current medications.

Editorial summary

Retatrutide is the first published triple-agonist obesity therapy to clear a Phase 3 efficacy bar. The Phase 2 data were already the largest weight reductions reported in this drug class at the time of publication; the first Phase 3 readout extended them. Side-by-side, retatrutide appears to outperform tirzepatide and semaglutide on absolute weight loss magnitude, with the caveat that head-to-head trials have not yet been done. The dysesthesia signal is the new finding to watch as the rest of the TRIUMPH program reads out, and the cardiovascular and kidney outcomes trial is the trial that will determine whether retatrutide is a weight-loss drug or a cardiometabolic-protective drug in the SELECT and FLOW sense.